Immune Response Post-SARS-CoV-2 mRNA Vaccination in Kidney Transplant Recipients Receiving Belatacept.

Abstract

The prevalence of seroconversion postvaccination to severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is weaker in recipients of a solid-organ transplant compared with healthy individuals. The impact of different immunosuppressive therapies on the immunologic response after SARS-CoV-2 mRNA vaccines in kidney transplant recipients (KTx) is still ill-defined. We assessed the specific humoral immunity response after SARS-CoV-2 mRNA vaccination in KTx receiving belatacept compared to KTx receiving tacrolimus. Between February 2011 and April 2021, we included patients who had received consecutive KTx (at least 1-y posttransplantation) from our outpatient clinic and had received 2 doses of SARS-CoV-2 mRNA vaccine (BNT162b2 or Moderna COVID-19). Maintenance immunosuppression was based on either belatacept (every 4 wk) or tacrolimus, in addition to mycophenolic acid. At the time of the first vaccination, patients had a negative SARS-CoV-2 serology. For those receiving belatacept, the SARS-CoV-2 mRNA vaccination was performed at day 21 post–belatacept infusion (to reduce impact on immunogenicity). Blood samples were collected at the time of the first vaccination, 1 mo after the first, the second, and the third vaccination. Humoral immune response was assessed using an enzyme immunoassay against the S1 domain of the SARS-CoV-2 spike protein (Wantai Biological Pharmacy Enterprise Co., Beijing, China). Fifty-seven patients were recruited: mean age was 62 ± 13 y. Immunosuppression was belatacept for 41 patients (72%) and tacrolimus for 16 patients (28%). Eighteen (31.5%) patients were female. Mean time from kidney transplantation was 122 ± 81 mo in the belatacept group and 174 ± 346 mo in the tacrolimus groups (P = 0.56). Overall, 21 patients (36%) had a positive immune response post–SARS-CoV-2 vaccination (after the third dose). Of these, after the second dose, 7 (17%) belatacept-treated patients and 9 (56%) tacrolimus-treated patients were tested positive for anti–SARS-CoV-2 antibodies (P = 0.003). After the third vaccination, 20 belatacept patients were assessed: 4 patients were positive (20%). Of these, 1 was positive after the second dose, and 3 were negative. Two positive patients after the second dose of vaccine have lost their immunity after the third dose. The anti–SARS-CoV-2 antibody titer increased significantly with the number of vaccinations (Figure 1), that is, 1.1 ± 4.7 after the first, 2.2 ± 5.7 after the second, and 3.3 ± 8 after the third SARS-CoV-2 mRNA vaccination.FIGURE 1.: Response to SARS-CoV-2 vaccination in Belatacept Kidney transplant recipients. A, Comparison of anti–severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) mRNA positive immune responses in kidney transplant recipients at month 3 after vaccination who were either on belatacept or on tacrolimus immunosuppressive regimen. B, Anti–SARS-CoV-2 mRNA antibody titers in kidney transplant recipients who received belatacept. The dot-plot shows all anti–SARS-CoV-2 mRNA titers at months 2 and 3 after vaccination. The red point shows the average; the red bar represents the interquartile. C, anti–SARS-CoV-2 mRNA positive immune responses in belatacept-treated kidney transplant recipients after the third vaccination.The immune response to SARS-CoV-2 vaccination is lower in KTx recipients compared with healthy populations.1 Herein, we confirm a low immune response (36%) after SARS-CoV-2 vaccination in KTx. In addition, KTx receiving belatacept had a significantly lower antibody response versus tacrolimus. This trend was also found by Chavarot et al (2021), who reported an antibody positivity of 5.7% in KTx receiving belatacept.2 However, in that study, the SARS-CoV-2 vaccination was given at the same time as belatacept infusion, which possibly minimized vaccine immunogenicity. Ou et al (2021) reported on 609 KTx. Of these, 19 had received belatacept-based immunosuppression, but only 5% of these patients had anti–SARS-CoV-2 antibodies.3 In our study, all patients received a vaccination at 21 d after belatacept infusion. This may explain the improved response to vaccination (ie, 17%) after the second vaccination. The serological Wantai assay is correlated to virus-neutralizing antibodies and is one with the higher sensitivity, which means that our results are not underestimated.4,5 In conclusion, belatacept significantly reduced the immune response to SARS-CoV-2 mRNA vaccination; however, delaying SARS-CoV-2 vaccination until 21 d after a belatacept infusion may improve immunogenicity.